Skip to content

Contact +44 (0) 20 7060 7474 email us

Drug Discovery

Currently Druggable in Colorectal Cancer

A Drug Target Competitive Analysis

Publication Date December 2008
Publisher Bioseeker
Product Type Report
Pages 301
ISBN Number not applicable
Product Code BSK00201

Price

£1,745.00
approximately: $2,642 | €1,948

pdf

Buy Now

Order above formats by FAX

Order by Fax

Summary

Not surprisingly, an increasing number of companies have turned their attention to the cancer targeted therapy market, undoubtedly trying to emulate the blockbuster status that several brands have already achieved.

This report aims to analyze the current and future potential of colorectal cancer pipeline by examining key fundamentals across the entire pipeline of drug candidates. BioSeeker has identified three fundamental dimensions to outline the competitive landscape within the pharmaceutical industry; compound type, therapy area and target type.
This report is written for you to identify your competition and understand which targeting strategies are at work within colorectal cancer drug development. It allows you to pin-point which competitors drugs' clinical out-come may have bearing on your own drug development and who are developing sequels to successful drugs. This report also helps you to locate white-spots in the competitive landscape, giving you little or no competition. Conversely it may reveal unexpected competition for you.

Drug targets are the critical link between drugs and their role in the treatment of medical disorders. BioSeeker has surveyed the colorectal cancer field and identified 120 drug targets belonging to 156 drugs. This report, Currently Druggable in Colorectal Cancer: A Drug Target Competitive Analysis is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of colorectal cancer drugs.

In the report, BioSeeker reports on 105 unique drug target combinations, each comprised of a different collection or mix of individually defined targets, for 156 colorectal cancer drugs. The highest degree of distinctiveness among the cancer drugs is achieved by sorting each of them according to drug target mix, compound type and R&D approach. At the same time we are also identifying peer groups of drugs, that is, drugs we consider suitable for head-to-head comparison during drug development.

To fuel the scientific and competitive thinking, BioSeeker opens the gate into the presence and relevance of protein-protein interactions between identified targets of colorectal cancer drugs. No less than 231 target-target interactions were recognized among and between 87 of the 120 included colorectal cancer drug targets.

Why You Should Own Your Own Copy of this Report:

300 pages, with more than 50 different tables and figures. Includes more than 1,000 active links to drug target related resources on the Internet
A 156 colorectal cancer drugs analysis, under development by 95 investigators
120 unique, in-depth, drug target validating profiles, highlighting twelve themes about the drug target, i.e. protein-protein interaction with other colorectal cancer drug targets, pursued cancer indications, drugs under development, presence in the Cancer Genome Project etc.
A unique drug target combination breakdown of colorectal cancer drugs into R&D approaches
Unique drug-protein target interactome- and protein-protein interactome of drug targets analysis
Pathway profiling of colorectal cancer drug targets
Compound strategies based on sub-cellular localization of drug targets
Expression levels of identified drug targets in malignant colorectal cancer tissue
Structure based drug design in colorectal cancer
Pin-point which competitor drugs' clinical out-come may have bearing on your own drug development
Who are working on sequels to blockbuster drugs?
Locate white-spots in the competitive landscape, giving you little or no competition

Contents

  • 1 Executive Summary
  • 2 About Cancer Highlights
  • 3 Methodologies
  • 4 Table of Contents
    • 4.1 List of Figures
    • 4.2 List of Tables
  • 5 How to Use this Report
  • 6 Compound Strategies based on Sub-Cellular Localization of Colorectal Cancer Drug Targets
  • 7 The Cancer Genome Project and Colorectal Cancer Targets
    • 7.1 Colorectal Cancer Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer
  • 8 Expression Levels of Identified Drug Targets in Colorectal Cancer Tissue
  • 9 Pathway Analysis of Colorectal Cancer Drugs
  • 10 Target-Target Interactions among Identified Colorectal Cancer Targets
  • 11 Structure-based Drug Design in Colorectal Cancer is Stimulated by Available StructureData on Biological Targets
  • 12 Drug Target Profiles of Colorectal Cancer Drugs
    • 12.1.1 Carboxy-lyase Activity Targets
    • 12.1.2 Catalytic Activity Targets
    • 12.1.3 Cell Adhesion Molecule activity Targets
    • 12.1.4 Cofactor Binding Targets
    • 12.1.5 Complement Activity Targets
    • 12.1.6 Cysteine-Type Peptidase Activity Targets
    • 12.1.7 Cytokine Activity Targets
    • 12.1.8 DNA Binding Targets
    • 12.1.9 DNA Topoisomerase Activity Targets
    • 12.1.10 DNA-Directed DNA Polymerase Activity Targets
    • 12.1.11 DNA-Methyltransferase Activity Targets
    • 12.1.12 G-Protein Coupled Receptor Activity Targets
    • 12.1.13 Glutathione Transferase Activity Targets
    • 12.1.14 Growth factor activity Targets
    • 12.1.15 Guanylate Cyclase Activity Targets
    • 12.1.16 Hormone Activity Targets
    • 12.1.17 Hydrolase Activity Targets
    • 12.1.18 Kinase Activity Targets
    • 12.1.19 Kinase Regulator Activity Targets
    • 12.1.20 Ligase Activity Targets
    • 12.1.21 Metallopeptidase Activity Targets
    • 12.1.22 Molecular Function Unknown Targets
    • 12.1.23 Motor Activity Targets
    • 12.1.24 Oxidoreductase Activity Targets
    • 12.1.25 Peptidase Activity Targets
    • 12.1.26 Peroxidase Activity Targets
    • 12.1.27 Protease Inhibitor Activity Targets
    • 12.1.28 Protein Binding Targets
    • 12.1.29 Protein Serine/Threonine Kinase Activity Targets
    • 12.1.30 Protein Threonine/Tyrosine Kinase Activity Targets
    • 12.1.31 Protein-Tyrosine Kinase Activity Targets
    • 12.1.32 Receptor Activity Targets
    • 12.1.33 Receptor Binding Targets
    • 12.1.34 Receptor Signaling Complex Scaffold Activity Targets
    • 12.1.35 Serine-Type Peptidase Activity Targets
    • 12.1.36 Structural Constituent Of Cytoskeleton Targets
    • 12.1.37 Transcription Factor Activity Targets
    • 12.1.38 Transcription Regulator Activity Targets
    • 12.1.39 Translation Regulator Activity Targets
    • 12.1.40 Transmembrane Receptor Activity Targets
    • 12.1.41 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
  • 13 The Drug-Target Interactome
  • 14 The Progression and Maturity of Colorectal Cancer Targets
    • 14.1 Target Profiles of Colorectal Cancer Drugs in Pre-Registration to Marketed
    • 14.2 New and Unique Colorectal Cancer Targets in Phase III Clinical Development
    • 14.3 New and Unique Colorectal Cancer Targets in Phase II Clinical Development
    • 14.4 New and Unique Colorectal Cancer Targets in Phase I Clinical Development
    • 14.5 New and Unique Colorectal Cancer Targets in Preclinical Development
    • 14.6 Development Profiles of All Colorectal Cancer Target Combinations
  • 15 Targets by R&D Approach in Colorectal Cancer
    • 15.1 Small Molecules
      • 15.1.1 Background
      • 15.1.2 Targets in Colorectal Cancer
    • 15.2 Peptide/Protein Drugs
      • 15.2.1 Background
      • 15.2.2 Targets in Colorectal Cancer
    • 15.3 Monoclonal Antibodies and Antibody-Like Structures
      • 15.3.1 Background
      • 15.3.2 Targets in Colorectal Cancer
    • 15.4 Nucleic Acid Therapies
      • 15.4.1 Background
      • 15.4.2 Targets in Colorectal Cancer
    • 15.5 Gene Therapy
      • 15.5.1 Background
      • 15.5.2 Targets in Colorectal Cancer
    • 15.6 Drug Delivery and Nanotechnology
      • 15.6.1 Background
      • 15.6.2 Targets in Colorectal Cancer
  • 16 Colorectal Cancer Targets by Companies
    • 16.1 Australia
    • 16.2 Canada
    • 16.3 China
    • 16.4 Cuba
    • 16.5 Denmark
    • 16.6 France
    • 16.7 Germany
    • 16.8 Israel
    • 16.9 Italy
    • 16.10 Japan
    • 16.11 Netherlands
    • 16.12 Norway
    • 16.13 South Korea
    • 16.14 Spain
    • 16.15 Switzerland
    • 16.16 Taiwan
    • 16.17 United Kingdom
    • 16.18 USA
    • 16.19 Non-Industrial Bodies
  • 17 Disclaimer
  • 18 Drug Index
  • 19 Company Index
  • 4.1 List of Figures
    • Figure 1: Distribution of Compound Types among Colorectal Cancer Drugs
    • Figure 2: Primary Sub-cellular Localization of Drug Targets
    • Figure 3: Visualization of Target-Target Interactions Among Colorectal Cancer Drug Targets
    • Figure 4: The Drug-Protein Interactome of Colorectal Cancer Drugs V The Main Cluster
    • Figure 5: The Drug-Protein Interactome of Colorectal Cancer Drugs V Smaller Clusters
    • Figure 6: Head-to-Head Targeting Interactome of Colorectal Cancer Drugs
  • 4.2 List of Tables
    • Table 1: Compound Strategies based on Sub-Cellular Localization of Colorectal Cancer Drug Targets
    • Table 2: Drug Targets of Colorectal Cancer Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census
    • Table 3: Expression Levels of Identified Drug Targets in Colorectal Cancer Tissue
    • Table 4: Pathway Summary
    • Table 5: Drug Targets without any Identified Assigned Pathways
    • Table 6: Pathway Profile According to BioCarta of Colorectal Cancer Drug Targets
    • Table 7: Pathway Profile According to KEGG of Colorectal Cancer Drug Targets
    • Table 8: Pathway Profile According to NetPath of Colorectal Cancer Drug Targets
    • Table 9: Target-Target Interactions among Colorectal Cancer Drug Targets
    • Table 10: Identity of Colorectal Cancer Drug Targets with Available Biological Structures
    • Table 11: Overview of Drug Target Profile Themes
    • Table 12: Drug-Protein Interactome Clusters
    • Table 13: Fall Out in Terms of the Total Number of Drug Target Mixes, Drugs, and the Presence of New Drug Target Mixes by Developmental Stage
    • Table 14: Top 5 Competitive Colorectal Cancer Targets
    • Table 15: Target Profiles of Colorectal Cancer Drugs in Pre-Registration to Marketed
    • Table 16: New and Unique Colorectal Cancer Targets in Phase III Clinical Development
    • Table 17: New and Unique Colorectal Cancer Targets in Phase II Clinical Development
    • Table 18 New and Unique Colorectal Cancer Targets in Phase I Clinical Development
    • Table 19: New and Unique Colorectal Cancer Targets in Preclinical Development
    • Table 20: The Progression, Maturity and Competitive Comparison of Colorectal Cancer Drug Targets in Development
    • Table 21: Number of Colorectal Cancer Drug Target Mixes Reported by Line of Therapy
    • Table 22: Number of Head-to-head Competing Small Molecule Drugs for the Treatment of Colorectal Cancer by Drug Target
    • Table 23: Drug Targets of Small Molecule Drugs in Colorectal Cancer
    • Table 24: Mechanistic Relationship between Small Molecule Drugs in Colorectal Cancer
    • Table 25: Drug Targets of Peptide Based Drugs in Colorectal Cancer
    • Table 26: Drug Targets of Protein Based Drugs in Colorectal Cancer
    • Table 27: Drug Targets of Monoclonal Antibodies and Antibody-Like Drugs in Colorectal Cancer
    • Table 28: Drug Targets of Nucleic Acid Therapies in Colorectal Cancer
    • Table 29: Vectors in Gene Therapy
    • Table 30: Drug Targets of Gene Therapies in Colorectal Cancer
    • Table 31: Drug Targets with New Drug Delivery Strategies in Colorectal Cancer
    • Table 32: Colorectal Cancer Drugs with Drug Target Mix and Developmental Stage by Companies in Australia
    • Table 33: Colorectal Cancer Drugs with Drug Target Mix and Developmental Stage by Companies in Canada
    • Table 34: Colorectal Cancer Drugs with Drug Target Mix and Developmental Stage by Companies in China
    • Table 35: Colorectal Cancer Drugs with Drug Target Mix and Developmental Stage by Companies in Cuba
    • Table 36: Colorectal Cancer Drugs with Drug Target Mix and Developmental Stage by Companies in Denmark
    • Table 37: Colorectal Cancer Drugs with Drug Target Mix and Developmental Stage by Companies in France
    • Table 38: Colorectal Cancer Drugs with Drug Target Mix and Developmental Stage by Companies in Germany
    • Table 39: Colorectal Cancer Drugs with Drug Target Mix and Developmental Stage by Companies in Israel
    • Table 40: Colorectal Cancer Drugs with Drug Target Mix and Developmental Stage by Companies in Italy
    • Table 41: Colorectal Cancer Drugs with Drug Target Mix and Developmental Stage by Companies in Japan
    • Table 42: Colorectal Cancer Drugs with Drug Target Mix and Developmental Stage by Companies in the Netherlands
    • Table 43: Colorectal Cancer Drugs with Drug Target Mix and Developmental Stage by Companies in Norway
    • Table 44: Colorectal Cancer Drugs with Drug Target Mix and Developmental Stage by Companies in South Korea
    • Table 45: Colorectal Cancer Drugs with Drug Target Mix and Developmental Stage by Companies in Spain
    • Table 46: Colorectal Cancer Drugs with Drug Target Mix and Developmental Stage by Companies in Switzerland
    • Table 47: Colorectal Cancer Drugs with Drug Target Mix and Developmental Stage by Companies inTaiwan
    • Table 48: Colorectal Cancer Drugs with Drug Target Mix and Developmental Stage by Companies in United Kingdom
    • Table 49: Colorectal Cancer Drugs with Drug Target Mix and Developmental Stage by Companies in USA
    • Table 50: Colorectal Cancer Drugs with Drug Target Mix and Developmental Stage by Non-Industrial Bodies